Topic Listing for Salix Pharmaceuticals

Aaipharma Llc Ability Increase Revenue Future Depend Part Success In-licensing
Able Follows Absence Certain Changes Events
Absence Litigation Absorption
Access Information Accounting Terms
Accounts Receivable Accrued Liabilities
Accrued Rights Surviving Obligations Aciphex Rabeprazole Sodium
Ackground Adam Derbyshire- Salix Pharmaceuticals Inc-cfo
Additional Abstracts Presented Ddw Further Support Safety Efficacy Additional Clinical Trials
Additional Conditions Obligations Iron Additional Conditions Obligations Steel Merger Sub
Additional Consequences Termination Additional Information
Additional Napo Representations Warranties Additional Salix Information
Additional Subsidiary Guarantors Address Principal Executive Offices Zip Code
Adjustment Changes Capitalization Administration
Administrative Agent Adults Aged
Adults Over Age Adverse Event Reporting Recalls Withdrawals
Adverse Events Patients Previously Treated Corticosteroids Adverse Experience Reporting Field Reports Quality Complaints
Advertising Costs Advisory Fiduciary Responsibility
Affiliate Agreements Affirmative Covenants Iron
Affirmative Covenants Steel Afternoon Colonoscopy
Against Novel Laboratories Agreement
Agreement Complements Eisais Presence Gastroentemltigy Primary Care Agreement Plan Merger
Alfa Wassermann Spa Allowance Rebates Chargebacks Coupons
Allowance Rebates Coupons Allowance Returns
Allowance Uncollectible Accounts Altana Pharma Focus Primary Care Physicians
Altana Pharma Inc Alw Partnership
Alw Partnership Terminates License Agreement Them Then Prevent Amendment
Amendment 2005 Stock Plan Amendment Termination
Amendments Registrants Code Ethics Amortization Product Rights Intangible Assets
Angela Larson Sig-analyst Announces Pricing Public Offering Common Stock
Annual Cash Incentive Payments Annual Meeting Stockholders Salix Pharmaceuticals Ltd Held 2009
Annual Report Annual Report Form 10-k
Anti-stacking Anticipated Sales Sanvar Product
Antitakeover Provisions Discourage Takeover Stockholders Consider Best Interests Anusol-hc Proctocort Hydrocortisone Creams Suppositories
Application Formatted Required Title Paragraph 31450 Code Federal Appointment Authority
Approval 2005 Stock Plan Approximately Americans Suffer Dibs
Apriso Apriso Mesalamine Extended-release Capsules 0375g
Aricept Donepezil Hci Tablets Aricept Donepezil Hcl Tablets
Asset Impairment Assignment
Audit Committee Report Audit Fees
Audit-related Fees Authority
Authorized Generic Watson Authorized Signatures Sign Here Completed Instructions Executed
Available Rights Salix Right Negotiation License Additional Napo Azasan Azathioprine Tablets
Balsalazide Disodium Tablets Balsalazide Tablet
Balsalazide Tablet Application Seeks Twice-a-day Dosing Reduced Pill Balsalazide Tablets Offer Twice-a-day Dosing Reduced Pill Burden
Balsalazide Tablets Twice-daily Effective Improving Signs Symptoms Mild-to-moderate Banc America Health Care Conference
Banc America Securities Conference Bank America 2007 Health Care Conference
Bank America 2008 Specialty Pharmaceuticals Conference Bank America Conference
Bank America Health Care Conference 2006 Bank America Merrill Lynch Conference
Base Salary Beneficial Ownership Reporting Compliance
Benefit Parties Beyond Travelers Diarrhea
Biorex Laboratories Limited Biotransformation
Blue Sky Bmo Capital Markets Conference
Bmo Conference Board Approval Vote Required
Board Committees Board Directors Compensation Structure
Board Directors Executive Compensation Board Directors Recommends Vote Following Proposals
Board Directors Unanimously Recommends Voting Nominees Listed Below Board Meetings Committees
Borrower Borrowings Conversions Continuations Committed Loans
Bout Alix Bout Raveler Iarrhea
Bout Rohn Isease Bout Tudy
Breach Napo Agreement 143 Indemnification Procedure Breach Napo Agreement Stylemargin-top12pxmargin-bottom0px Text-indent4 143 Indemnification Procedure
Brokers Budenofalk 2mg Rectal Foam
Budenofalk 3mg Gastro-resistant Capsules Budesonide
Budget Summary Snda Filing Crofelemer Treatment Chronic Hiv Campylobacter Jejuni Gastrointestinal Infection
Capitalization Capped Price
Carolyn Logan -salix Pharmaceuticals Inc-president Ceo Carolyn Logan- Salix Pharmaceuticals Inc-president Ceo
Cash Equivalents Cautionary Statement
Cedars Sinai Medical Center Cedars-sinai Medical Center
Certain Adjustments Certain Cpl
Certain Definitions Certain Development Costs
Certain Napo Employees Certain Relationships Related Transactions
Certain Relationships Related Transactions Director Independence Certain Residual Payments
Certain Salix Competitors Certain Transactions
Certificate Incorporation Bylaws Certification
Certification Against Patent Moviprep Change Control Licensee
Change Control Napo Acquisition Change Vote After Submitting
Changes Internal Control Over Financial Reporting Changes Specifications
Children Cibc Conference
Cibc World Markets Conference Clinical Development Capital Partnership
Clinical Laboratory Evaluation Clinical Laboratory Evaluations
Closing Clostridium Difficile -associated Diarrhea
Co-promotion Agreement Co-promotion Agreement Eisai Inc
Co-promotion Creates Approximately 700-member Combined Sales Effort Co-promotion Fee
Co-promotion Reaffirms 2005 Guidance Code Business Conduct Ethics
Colazal Colazal -related Data Presented Poster Presentations
Colazal 1100 Tablet Formulation Trial Initiated Ulcerative Colitis Colazal Balsalazide Disodium
Colazal Balsalazide Disodium Capsules Colazal Balsalazide Disodium Capsules 750
Colazal Food Effect Application Granted Fda Approval Colazal Pediatric Exclusivity Filing Submitted
Colazal Pediatric Exclusivity Granted Collaboration Agreement
Collaboration Management Collaborative Agreements
Collaborative Product Acquisition Agreements Colorectal Cancer Screening
Commercial Supply Commercialization
Commercialization Licensed Products Commitments
Commitments Credit Extensions Common Stock
Communications Board Directors Communications Regulatory Authorities
Compassionate Distribution Countries Compassionate Distribution Napo Pediatric Products
Compensation Chief Executive Officer Compensation Committee Interlocks Insider Participation
Compensation Committee Report Compensation Directors
Compensation Discussion Analysis Compensation Non-employee Directors
Competition Completes Sale 6325 Shares Common Stock
Completion Acquisition Disposition Assets Compound Equipment Usage
Compound-related Specifications Comprehensive Income
Comprehensive Income Loss Comprehensive Loss Income
Computation Interest Fees Retroactive Adjustment Applicable Rate Concerning Noteholders
Conclusion Regarding Effectiveness Disclosure Controls Procedures Conditions Obligations Initial Purchasers
Conditions Obligations Steel Merger Sub Iron Effect Conference Call Information
Conference Call Web Cast Conference Call Webcast
Confidential Information Confidentiality
Confidentiality Non-disclosure Confidentiality Non-use
Confidentiality Publications Conflict Required Filings Consents
Consent Independent Registered Public Accounting Firm Consenting Lender
Consequences Termination Consideration
Consolidated Balance Sheet Data Consolidation Merger Sale Conveyance Lease
Continue Face Challenges Integrating Inkine Operations Personnel Continuing Director Education
Continuing Medical Education Activities Contribution
Control Procedures Controls Procedures
Conversion Securities Convertible Notes
Convertible Notes Offering Convertible Senior Notes
Corporate Governance Guidelines Cost Products Sold
Costs Expenses Counterparts
Covenants Cowen 27th Annual Health Care Conference
Cowen Annual Health Care Conference Cowen Conference
Cpl-related Specifications Creation Direct Financial Obligation Off-balance Sheet Arrangement
Credit Agreement Credit Facility
Credit Suisse Conference Critical Accounting Policies
Crofelemer Crofelemer Tablet Components
Crohns Disease Currency Method Payment Payments Pursuant Agreement Shall Salix
Current Capacity Cytochrome P450
D-79041 Freiburg Daily Board Directors Meeting Fees
Data Demonstrate Rifaximin Significantly Improved Critical Flicker Frequency Data Exclusivity
Ddw Deadline Receipt Stockholder Proposals
Debarment Exclusion Debiopharm Group
Debiovision License Option Debiovision Patent Rights
Dedicated Hiv Employees Default Several Initial Purchasers
Definitions Delivery
Delivery Documents Stockholders Sharing Address Departure Directors Principal Officers Election Appointment
Dependent Parties Manufacture Products Dependent Parties Supply Products
Description Description Composition Drug Product Crofelemer Enteric-coated Tablets Used
Description Pre-booking Activities Development
Development Activities Development Commercialization License Agreement
Development License Agreement Development Plan Budget
Diabetic Gastroparesis Difficile-associated Diarrhea
Difficile-associated Diarrhea Cdad Digestive Disease 2007
Directions Annual Meeting Directions Salix Pharmaceuticals Ltd 2009 Annual Meeting
Director Compensation 2007 Director Compensation 2008
Director Compensation Philosophy Director Independence
Director Nominees Directors Executive Officers Corporate Governance
Directors Executive Officers Registrant Directors Officers
Disclosure Disclosures
Dispute Resolution Dissenters Rights
Distribution Distribution Rights Obligations
Dividend Policy Document Summary
Documents Documents Incorporated Reference
Dollars Dose Ranging Study
Driving Directions Annual Meeting Drug Product
Due Diligence Ecitals
Effect Merger Effect Termination
Effective Time Eisai Inc
Elderly Election Directors
Eligibility Elimination
Emerald Investment Forum Employee Benefit Matters
Employee Benefit Plans Employees
Employment Agreement Employment Agreements Change Control Arrangements
Encephalopathy Enforcement
Enforcement Patents English Language
Entire Agreement Entire Agreement Severability
Entry Material Definitive Agreement Entry Material Definitive Agreements
Environmental Matters Equity Compensation
Equity Compensation Plan Information Equity Grants Exercises Holdings
Erisa Compliance Ermination Romotion Greement
Estimates Event Notices
Events Default Remedies Evidence Debt
Exact Name Registrant Specified Charter Example Calculation Profit Per Prescription
Example Payment Calculation Example Profit Share Calculation
Example Scale-up Plan Exchange Certificates
Exclusivity Execution Version
Executive Compensation Executive Compensation Other Matters
Executive Compensation Philosophy Executive Compensation Philosophy Objectives
Executive Officers Registrant Exemption Liability
Exercise Notice Exhibits
Exiting Lender Expect Unprofitable Experience Negative Cash Flow 2008 Need
Expect Unprofitable Experience Negative Cash Flow 2009 Need Expenses
Expenses Indemnity Damage Waiver Explanatory
Exposed Significant Product Liability Claims Prevent Interfere Commercialization Extension Waiver
Failure Comply Manufacturing Regulation Harm Financially Hurt Reputation Failure Manage Growth Increase Expenses Faster Revenue
Fair Value Financial Instruments Fairness Opinion
Falk Patents Falk Pharma
Falk Pharma Europe Falk Pharma Gmbh
Fda Review Response Due 2006 Federal Income Tax Consequences Relating 2005 Stock Plan
Fees Costs Related License Agreements Fees Earned Paid Cash
Fees Expenses Other Payments Final Execution Copy
Financial Covenants Financial Statements
Financial Statements Exhibits Financial Statements Material Adverse Effect
Financial Statements Supplementary Data Financial Terms
Find Additional Information Find Voting Results Meeting
Fixed Price Focused Exclusively Gastroenterology
Force Majeure Forecasts Orders Delivery Acceptance
Foreign Currency Translation Form 10-k
Form 10-q Form Merck Fda Letters
Form Salix Fda Letters Former Address Changed Last Report
Forward-looking Statements Frequency Bowel Healing Well Emotional Social Functions
Friedman Billings Ramsey Conference Fully-allocated Manufacturing Costs
Further Action Commercially Reasonable Efforts Further Assurance
Future Sales Colazal Significantly Less Historical Due Approval Future Sales Colazal Xifaxan Other Marketed Products Might
Future Sales Xifaxan Other Marketed Products Might Less Gastroenterology Update
General General Compensation Philosophy
General Disorders General Provisions
Glenmark Territory Global Coordination
Governing Law Governing Law Jurisdiction
Governing Law Jurisdiction Etc Governing Law Provisions
Government Regulation Grant Co-promotion Rights Minimum Number Details
Grant License Grant Plan-based Awards 2007
Grant Rights Grants Plan-based Awards 2006
Grants Plan-based Awards 2008 Granulated Mesalamine
Half Risk Colorectal Cancer Not Screenings He-related Hospitalization
Headings Held 2005
Held 2006 Held 2007
Held 2008 Held 2009
Helicobacter Pylori Infection Hepatic Encephalopathy
Householding Matters Hsr Act Matters
Ibs Ibs Market Opportunity Exceeds
Immediate Release Immune System Disorders
Implementation Lifecycle Management Plan Improvements Quality Life
Incentive Stock Options Income Taxes
Incorporation Increased Costs Reserves Eurodollar Rate Loans
Indemnification Indemnification Limitations
Indemnification Rights Indemnity
Indenture Independent Registered Public Accounting Firm
Index Consolidated Financial Statements Infection
Inflammatory Bowel Disease Information 2007 Change Independent Registered Accounting Firm
Information Concerning Solicitation Voting Information Regarding Meetings
Information Regarding Meetings Board Committees Information Reporting
Infringement Infringement Claims Parties
Infringement Intellectual Property Inkine
Inkp-102 Inkp-102 Presented Poster Presentations
Inkp-102 Versus Visicol Tablets Insurance
Intangible Assets Intangible Assets Goodwill
Intellectual Property Intellectual Property Initial Filings Ownership
Intellectual Property Licences Intellectual Property Ownership Maintenance Prosecution
Intellectual Property Rights Might Not Afford Meaningful Protection Intellecutual Property Relating Rifaximin
Intense Competition Might Render Products Noncompetitive Obsolete Interest
Interest Other Income Expense Net Interest Other Income Net
Internal Control Internal Revenue Code 1986
Introduction Invalidity Unenforceability Defenses Actions
Inventories Inventory
Inventory Allowance Investment Conferences
Investments Irrigation Requirements
Irritable Bowel Syndrome Irritable Bowel Syndrome Ibs
Iscellaneous Issuance Xifaxan Patent
Issued Patent Licensed Napo Issued Patents Assigned Napo
Issues Jmp Securities Conference
Joint Proxy Statement Prospectus Registration Joint Steering Committee
Joint Steering Committee Management Relationship King Pharmaceuticals Inc
Labor Relations Launch Visiclear Japan
Lease Agreements Legal Proceedings
License Agreement License Grants
License Supply Agreement License Supply Agreement 7th 2005 Between
Licensed Trademarks Licensee Diligence Launch Lifecycle Management Plan
Licenses Permits Compliance Laws Licensors Obligations
Licensors Supply Obligations Limitations Liability
Liquidity Capital Resources Loan
Long Access Proxy Materials Internet Long-term Equity Incentives
Long-term Maintenance Mesalamine Granules Patients Previously Treated Corticosteroids Long-term Safety Analysis
Low Screening Rates Lupin
Maintenance Prosecution Defence Maintenance Remission Ulcerative Colitis
Managements Discussion Analysis Financial Condition Results Operations Managements Report Internal Control Over Financial Reporting
Manufacture Manufacturing
Manufacturing Know-how Margin Regulations Investment Act
Market Assumptions Market Registrants Common Equity Related Stockholder Matters Issuer
Marketing Plan Marketing Plan Meaning Set Forth Agreement
Master Purchase Sale License Agreement Material Contracts
Materials Maximum Monthly Whole Lot Quantities
Mayoly-spindler Sas Menarini Pharmaceutical Industries Srl
Merck Merck Inc
Merger Merger Inkine Pharmaceutical
Mesalamine Delayed-release Tablet Asacol Recovery Fecal Samples Mesalamine Granules
Metabolism Nutrition Disorders Method Administration
Metoclopramide Metoclopramide-zydis
Metoclopramide-zydis Facetimes New Roman Size1 Metozolv Metoclopramide Orally Disintegrating Tablets
Metozolv Odt Metozolv Odt Metoclopramide Hcl 5mg 10mg Orally Disintegrating
Michael Freeman Michael Freeman- Salix Pharmaceuticals Inc-executive Director-investor Relations Corporate
Michael Tong Wachovia-analyst Mild Moderately Active Crohns Disease
Mild-moderate Crohns Disease Milestone Payments
Milestones Milestone Payments Minimum Payment Obligations
Miscellaneous Miscellaneous Provisions
Mitigation Obligations Replacement Lenders Monday Poster Presentation Highlights
Monday Xifaxan Posters Moviprep
Moviprep Peg 3350 Sodium Sulfate Chloride Potassium Ascorbate Musculoskeletal Connective Tissue Bone Disorders
Name Person Filing Proxy Statement Other Registrant Napo Patents
Napo Pharmaceuticals Inc Napo Technology
Nasdaq Listing Ncinvest Conference
Nda Submission Continues Track Half 2010 Nda Submission Targeted
Negative Covenants Iron Negative Covenants Steel
Net Income Net Income Loss
Net Income Loss Per Common Share Net Income Loss Per Share
Net Income Per Share Net Loss Income Per Common Share
Net Sales Profits Reports New Tablet Bowel Cleansing Prep Colonoscopy-
New Two-liter Liquid Bowel Cleansing Prep Colonoscopy- Next Page Signature
Nominees Non-absorbed Gut-selective Antibiotic Novel Treatment Ibs Symptoms
Nonclinical Plans Nonstatutory Stock Options
Norgine Not Maintain Profitability Incur Losses Future Then Value
Not Maintain Recently Attained Profitability Incur Losses Future Noteholders Meetings
Notice Notice Infringement
Notice Restricted Stock Grant Notice Stock Option Grant
Notices Notices Effectiveness Electronic Communication
Novel Laboratories Nrl944
Number 000-23265 Salix Pharmaceuticals Ltd Offer Improved Convenience
Officers Directors Officers Surviving Corporation
Older Patients Online Also Help Environment Consenting Receive Electronic Delivery
Onsequences Ermination Operating Committee
Opinion Financial Advisor Option Exercises 2006
Option Exercises Stock Vested 2007 Option Exercises Stock Vested 2008
Option Grants Exercises Holdings Year-end Values Oral Presentation Saturday 830 845 General Session
Oral Presentation Sunday 2009 1030 1045 144 Oral Presentation Sunday 2009 930 945
Organization Basis Presentation Organization Qualification
Organization Qualification Subsidiaries Osmoprep
Osmoprep Versus Visicol Comparison Overall Ascending Colon Cleansing Osmoprep Versus Visicol Irrigation Requirements Colonoscopy
Otc Fleet Phospho-soda Ez-prep Bowel Cleansing System Other
Other Director Not Standing Re-election Meeting Other Events
Other Fees Other Information
Other Matters Other Rifaximin Presentations Ddw
Other Rifaximin-related Presentations Acg Outstanding Equity Awards 2007 Year-end
Over Overall Summary Program Activities
Overgrowth Irritable Bowel Syndrome Overview
Ownership Intellectual Property Ownership Intellectual Property Rights
Ownership Property Liens Perfection Matters Pacific Growth Equities 2006 Life Sciences Conference
Pacific Growth Equities Conference Part
Part Other Information Partial Unenforceability
Participants Merger Solicitation Partners Conference
Party Party Beneficiaries
Party Licenses Party Manufacturer
Party Manufacturer License Party Patents
Patent Covers Rifaximin Ibs Patent Maintenance Prosecution
Patent Prosecution Maintenance Patent Protection Provided 2024
Patient Preference Patients Maintenance Remission Ulcerative Colitis
Payment Expenses Payment General
Payments Payments Generally Administrative Agents Clawback
Peer Group Compensation Data Pending Applications Assigned Napo
Pepcid Famotidine Oral Suspension Diuril Chlorothiazide Performance Graph
Perimeter Park Drive Morrisville North Carolina Perimeter Park Drive Morrisville North Carolina 27560
Perquisites Pharmaceutical Focused Gastroenterology
Pharmacovigilance Agreement Pharmatel Pty Limited
Phase Study Phase Trial
Phase Trials Target Piper Jaffray Conference
Piper Jaffray Health Care Conference Plan
Please Please Materials Provided Herein Contain Projections Other Forward-looking
Polyp Detection Rate Posology
Poster 279 Poster 673
Poster 682 681 Poster Presentation 305 Poordad
Poster Presentation 306 Brown Poster Presentation Thursday 800 830 207
Poster Presentation Thursday 800 830 222 Poster Presentations
Poster T1202 Poster T1204
Potential Acute Chronic Diarrhea Markets Potential Milestone Payments
Potential New Two-liter Liquid Bowel Cleansing Prep Colonoscopy- Potential Treatment Acute Esophageal Variceal Bleeding
Pouchitis Pre-clinical Clinical Supply Obligations
Preferred Stock Prepayments
Prescription Reporting Methodology Presentation
Press Release Prevention Acute Radiation-induced Proctosigmoiditis
Prevention Travelers Diarrhea Price Costs
Price Inventory Principal Accountant Fees Services
Procedural Rules Product Medical Inquiries
Product Out-license Collaborations Product Supply
Product Trademarks Product Warranty Limitations
Products Profit Share
Promotional Allowances Promotional Materials
Promotional Materials Activities Propellant
Properties Properties Assets
Property Equipment Proposals Board Directors Recommends Vote Nominees Listed Following
Proposed Timelines Protection Flare-ups Once-daily Dose
Protective Role Rifaximin 550 Tablet 1100 Daily Hepatic Provision Income Tax
Proxy Solicited Behalf Board Directors Proxy Voted Directed Direction Indicated Listed Nominees Election
Public Announcements Purchase Agreement
Purchase Order Commitments Purchase Orders
Purchase Orders Forecasts Purchase Sale Delivery Notes
Purpose Pursuant Requirements Securities Exchange Act 1934 Form 10-k
Pursuant Requirements Securities Exchange Act 1934 Registrant Duly Pylori Gastritis
Quality Control Quality Life Benefits Ibs Symptom Severity Predictor Clinical
Quantitative Qualitative Disclosures Market Risk Quarterly Results Operations
Radiation Damage Prostate Cancer Patients Rationale Merger
Realized Loss Foreign Currency Translation Recall Withdrawal Contact Information
Recently Issued Accounting Pronouncements Recently Issued Accounting Pronouncements Not Yet Adopted
Recitals Record Date Shares Outstanding
Records Regulatory Matters Records Reports
Rectal Ulcer Redemption
References Regional Poa
Registrants Telephone Number Including Area Code Registrants Telephone Number Including Area Code 919 862-1000
Registration Statement Joint Proxy Prospectus Regulation Disclosure
Regulation Drug Compounds Outside United States Regulatory Approval Even Granted Might Entail Ongoing Requirements
Regulatory Approval Product Candidates Time-consuming Expensive Uncertain Result Regulatory Compliance
Regulatory Documentation Regulatory Interactions
Regulatory Matters Regulatory Other Matters
Reimbursement Initial Purchasers Expenses Related Companies
Relationship Parties Relationships
Release Rifaximin Product Reliance Administrative Agent
Rely Parties Sales Outside United States Other Markets Remainder Page Been Intentionally Left Blank
Repayment Loans Report Independent Registered Public Accounting Firm
Report Independent Registered Public Accounting Firm Financial Statements Report Independent Registered Public Accounting Firm Internal Control
Report Independent Registered Public Counting Firm Internal Control Reporting
Reports Records Representations
Representations Covenants Representations Indemnities Survive Delivery
Representations Warranties Representations Warranties Agreements Initial Purchasers
Representations Warranties Covenants Representations Warranties Iron
Representations Warranties Steel Representatives
Required Vote Research Analyst Independence
Research Development Restricted Cash
Restricted Stock Restrictive Covenants
Results Results Operations
Results Operations Financial Condition Results Operations Might Fluctuate Period Failure Meet Expectations
Results Study Presented European Association Liver Easl Annual Revenue Collaborative Agreements
Revenue Recognition Revenues
Revised Acg Guidelines Ibs Incorporate Rifaximin Revocability Proxies
Rifaximin Rifaximin 550 Twice Daily Significantly Improved Critical Flicker
Rifaximin Favorable Long-term Safety Profile Maintenance Remission Overt Rifaximin Phase Non-constipation Ibs Trial Initiated
Rifaximin Product Rifaximin Xifaxan Studied Investigator-initiated Trials
Rodman Renshaw Global Healthcare Conference Roth Capital Conference
Roth Capital Partners Conference Roth Conference
Royalty Royalty Rates
Safe Harbor Statement Safe Harbor Statement Private Securities Litigation Reform Act
Safety Safety Efficacy
Safety Profile Sales Marketing
Salix Salix Delivers 013 Eps
Salix Hiv Aids Pediatric Territory Salix License
Salix List Trademarks Logos Salix Pharmaceutical Products
Salix Pharmaceuticals Salix Pharmaceuticals Announces Acceleration Stock Option Vesting
Salix Pharmaceuticals Announces Appointment William Forbes Pharm Vice Salix Pharmaceuticals Announces Proposed Convertible Offering
Salix Pharmaceuticals Development Update Salix Pharmaceuticals Host Analyst Novmeber
Salix Pharmaceuticals Inc Mesalamine Controlled Release Capsules Salix Pharmaceuticals Ltd
Salix Pharmaceuticals Ltd Comparative Indexes Salix Pharmaceuticals Ltd Comparative Indices
Salix Pharmaceuticals Ltd Subsidiaries Salix Pharmaceuticals Present Ubs Conference
Salix Pharmaceuticals Receives Approvable Letter Fda Balsalazide Tablet Salix Pharmaceuticals Reports Digestive Disease 2006 Update
Salix Regulatory Reporting Contacts Salix Secures 100 Senior Secured Credit Facility
Salix Stock Price Performance Graph Salix Target Physicians
Salix Territory Salixs Payment Obligations Development Other Activities Indications
Salixs Payment Obligations Development Other Activities Respect Advent Sample Co-promotion Fee Calculation
Sample Policies Procedures Sanvar
Sanvar 600 Vials Vapreotide Acetate Powder Satisfaction Discharge
Schedule Schedule 1109
Schedule 1115 Schedule 117
Schedule 119 Schedule 124
Schedule 131 Schedule 134
Schedule 138 Schedule 140
Schedule 141 Schedule 155
Schedule 158 Schedule 160
Schedule 181 Schedule 182
Schedule 188 Schedule 312
Schedule 419 Schedule 632
Schedule 651 Schedule 816
Schedule Valuation Qualifying Accounts Schedules
Scott Hirsch Credit Suisse-analyst Scott Hirsch- Credit Suisse-analyst
Sec Filings Financial Statements Sec Filings Steel Financial Statements
Secretory Diarrhea Secures License Agreement Cedars-sinai Medical Center-
Securities Exchange Act 1934 Securities Registered Pursuant Act
Security Ownership Certain Beneficial Owners Management Related Stockholder Segment Reporting
Selection Nominees Board Directors Selling General Administrative
Severability Severe Crohns Disease
Severity Baseline Symptoms Predictor Clinical Response Shipping Handling Costs
Shire Pharmaceuticals Group Plc Signature
Signature Below Indicates Agreement Understanding Grant Subject Terms Signature Page Follow
Signature Page Follows Signatures
Significant Concentrations Sirgo Board Directors
Skin Subcutaneous Tissue Disorders Small Bowel Bacterial Overgrowth
Small Intestinal Bacterial Overgrowth Small Intestinal Bacterial Overgrowth Irritable Bowel Syndrome
Solicitation Solicitation Proxies
Sources Information Specific Compensation Programs
Specific Patient Populations Liver Diseases Specifications
Spread Stability Testing Crofelemer Tablets
State Other Jurisdiction Incorporation Steel Board Directors
Steel Employee Benefit Plans Steroid-binding Compounds
Stock Bonuses Stock Bonuses Restricted
Stock Options Stock Options Scheduled Expire 2010
Stock Ownership Guidelines Stock Plans
Stock Price Volatile Stock Purchase Rights
Stock-based Compensation Stockholder Proposals
Stockholder Rights Plan Stockholders Equity
Study Study Results Highly Statistically Significant P00001
Sublicenses Sublicensing
Submission Matters Vote Security Holders Subsequent Actions
Subsequent Events Subsidiary Guarantor Acknowledgement Consent
Successors Assigns Summary
Summary Compensation Table Summary Fees
Summary Licensed Iowa Summary Product Characteristics
Summary Significant Accounting Policies Summary Solid Oral Dosage Form Development
Sunday Poster Presentation Highlights Suntrust Robinson Humphrey Conference
Supplemental Indentures Supplemental Non-cash Disclosure
Supply Supply Chain
Supply Distribution Agreement Supply Distribution Agreement Watson Pharma Inc
Supply Price Swing Line Loans
Symptomatic Documented Gastroesophageal Reflux Disease Gerd Table Contents
Tablet Bowel Cleanser Patented Europe 2016 Tablet Bowel Cleansing Prep Colonoscopy Approved United Kingdom-
Takeover Provisions Inapplicable Target
Tax Accounting Treatment Merger Tax Deductibility Executive Compensation
Tax Fees Tax Matters
Tax Treatment Taxes
Term Termination Termination
Termination Agreement Termination Material Definitive Agreement
Terms Conditions Restricted Stock Grant Terms Stock Rights
Testing Samples Release Therapeutic Indications
Third-party Payors Not Provide Coverage Reimburse Patients Products Thomas Weisel Partners Conference
Thomas Weisel Partners Healthcare Conference Thomas Weisel Partners Healthcare Conference 2007
Three-month Nine-month Periods 2005 2004 Three-month Nine-month Periods 2006 2005
Three-month Periods 2005 2004 Three-month Periods 2006 2005
Three-month Periods 2007 2006 Three-month Six-month Periods 2005 2004
Three-month Six-month Periods 2006 2005 Total Product Revenue
Trade Marks Domain Names Trademark Registrations
Training Sales Meetings Transaction Terms
Transactions Related Persons Transfer Books
Transfer Ownership Travelers Diarrhea
Travelers Diarrhea Prevention Travelers Diarrhea Prevention Study
Treatment Iron Options Warrants Treatment Metoclopramide Cause Tardive Dyskinesia Serious Movement Disorder
Treatment Metoclopramide Longer Avoided Rare Cases Therapeutic Benefit Trustee
Tuesday Osmoprep Xifaxan Posters Tuesday Poster Presentation Highlights
Twice-daily Dosing Stands Improve Patient Compliance Ubs Conference
Ubs Global Pharmaceuticals Conference Ulcerative Colitis
Unauthorized Sales United States
Unlawful Payments Unresolved Staff Comments
Valid Claim Either Valid Issuances
Validation Processing Related Services Validation Services
Valuation Allowance Deferred Tax Assets Vapreotide Acetate
Vascular Disorders Versus Placebo Percent
Very Rare Visicol
Visicol Facetimes New Roman Size1 Osmoprep Sodium Phosphate Visicol Osmoprep Sodium Phosphate Monobasic Monohydrate Usp Dibasic
Visicol Sodium Phosphate Monobasic Monohydrate Usp Dibasic Anhydrous Vote Meeting
Vote Required Vote Shares Person Meeting
Vote Shares Without Attending Meeting Voting
Wachovia Conference Wachovia Securities Healthcare Conference
Waiver Amendment Credit Agreement Waiver Non-exclusion Remedies
Warranties Undertakings Warrants
Wednesday Xifaxan Poster Wells Fargo Conference
What Difference Between Holding Shares Stockholder Record Beneficial What Proposals Voted Meeting
What Quorum Requirement Meeting Whereas
William Blair Conference Wilmington Pharmaceuticals Llc
Witnesseth Xifaxan
Xifaxan Ibd Clinical Development Programs Progressing Xifaxan Investigated Crohns Disease Small Bowel Bacterial Overgrowth
Xifaxan Investigated Pouchitis Xifaxan Rifaximin
Xifaxan Rifaximin Tablets Xifaxan Size1 Rifaximin Tablets
Xifaxan Studied Investigator-initiated Trials Xifaxan Treatment Irritable Bowel Syndrome
Year-end Option Values Yumi Odonnah
Yumi Odonnah Thomas Weisel-analyst Zeria Pharmaceutical Ltd
Zydis Technology Provides Fast-dissolving Patient-friendly Formulation 
Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki